NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,692 | -21.4% | 2,377,978 | -0.1% | 0.00% | 0.0% |
| Q2 2023 | $23,776 | +3.6% | 2,379,873 | -7.9% | 0.00% | 0.0% |
| Q1 2023 | $22,954 | -35.7% | 2,584,751 | -20.6% | 0.00% | -50.0% |
| Q4 2022 | $35,726 | -99.9% | 3,253,736 | -9.8% | 0.01% | -25.0% |
| Q3 2022 | $46,991,000 | -19.7% | 3,606,352 | -22.0% | 0.01% | +14.3% |
| Q2 2022 | $58,546,000 | -13.1% | 4,620,823 | -3.9% | 0.01% | 0.0% |
| Q1 2022 | $67,336,000 | -52.3% | 4,806,289 | -1.3% | 0.01% | -46.2% |
| Q4 2021 | $141,018,000 | -0.3% | 4,871,084 | +3.2% | 0.01% | 0.0% |
| Q3 2021 | $141,378,000 | +31.5% | 4,718,877 | +16.5% | 0.01% | +30.0% |
| Q2 2021 | $107,486,000 | +11.8% | 4,051,478 | +31.0% | 0.01% | 0.0% |
| Q1 2021 | $96,183,000 | +394.4% | 3,093,705 | +422.9% | 0.01% | +400.0% |
| Q4 2020 | $19,453,000 | -1.0% | 591,636 | +5.1% | 0.00% | 0.0% |
| Q3 2020 | $19,645,000 | – | 562,746 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |